
CLAIMS

1. A compound of Formula I:



(I),

a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing,

wherein:


- Ring A is a phenyl, a 5-membered heteroaryl ring, or a 6-membered heteroaryl ring;
- Ring B is a pyridinyl ring;
- Ring D is a phenyl ring, a 5-membered heterocyclyl ring, a 6- membered heterocyclyl ring, a 5-membered heteroaryl ring, or a 6-membered heteroaryl ring;
- X is O, NH, or an N(C1-C4 alkyl);
- each R^1 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;
- m is 0, 1, 2, 3, or 4;
- each R^2 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;
- n is 0, 1, or 2;
- each R^3 is methyl;
- each R^4 is independently chosen from halogens, an oxo group, a hydroxyl group, a cyano group, and -$(Y)_k$-R^7 groups, or optionally two R^4, together with the

atom(s) they are attached to, form a 5-6 membered cycloalkyl or heterocyclyl ring that is optionally and independently substituted with one or more groups chosen from halogens, C_1-C_2 alkyl groups, haloalkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; wherein:


- k is 0, 1, 2, 3, 4, 5, or 6;
- each Y is independently chosen from $C(R^5)(R^6)$ groups, –O–, and $–NR^a–$ groups, wherein a heteroatom in $-(Y)_k-R^7$ is not bonded to another heteroatom in $-(Y)_k-R^7$, wherein:
  - each R^5 and R^6 is independently chosen from hydrogen, halogens, a hydroxyl group, C_1-C_4 alkyl groups, and C_{3-5} cycloalkyl groups, or R^5 and R^6 on the same carbon together form a C_{3-5} cycloalkyl group or oxo;
  - each of R^5 and R^6 is optionally independently substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, halogens, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and
  - each R^a is independently chosen from hydrogen and C_1-C_2 alkyl groups; and
- R^7 is chosen from hydrogen, halogens, a cyano group, and C_3-C_{10} cycloalkyl groups optionally substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, and halogens;

- q is 1, 2, 3 or 4; and
- Z is a divalent linker of formula $(L)_r$, wherein:
  - r is 1, 2, 3, 4, 5, or 6;
  - each L is independently chosen from $C(R^8)(R^9)$ groups, –O–, and $–NR^b–$ groups, wherein a heteroatom in Z is not bonded to another heteroatom in Z, wherein:
    - each R^8 and R^9 is independently chosen from hydrogen, halogens, C_1-C_2 haloalkyl groups, C_1-C_2 alkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and
    - each R^b is independently chosen from hydrogen and C_1-C_2 alkyl groups.

2. The compound of claim 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein the compound of Formula I is a compound of Formula II-A or II-B:



(II-A) or



(II-B),

a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing,


wherein:

- the carbon denoted by * has S-stereochemistry or R-stereochemistry;
- Ring A is a phenyl, a 5-membered heteroaryl ring, or a 6-membered heteroaryl ring;
- Ring B is a pyridinyl ring;
- Ring D is a phenyl ring, a 5-membered heterocyclyl ring, a 6-membered heterocyclyl ring, a 5-membered heteroaryl ring, or a 6-membered heteroaryl ring;
- each R^1 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;
- m is 0, 1, 2, 3, or 4;


- each R^2 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;
- n is 0, 1, or 2;
- each R^3 is methyl;
- each R^4 is independently chosen from halogens, a hydroxyl group, an oxo group, a cyano group, and -$(Y)_k$-R^7 groups, or optionally two R^4, together with the atom(s) they are attached to, form a 5-6 membered cycloalkyl or heterocyclyl ring that is optionally and independently substituted with one or more groups chosen from halogens, C_1-C_2 alkyl groups, haloalkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups, wherein:
  - k is 0, 1, 2, 3, 4, 5, or 6;
  - each Y is independently chosen from $C(R^5)(R^6)$ groups, –O–, and –NR^a– groups, wherein a heteroatom in -$(Y)_k$-R^7 is not bonded to another heteroatom in -$(Y)_k$-R^7, wherein:
    - each R^5 and R^6 is independently chosen from hydrogen, halogens, a hydroxyl group, C_1-C_4 alkyl groups, and C_{3-5} cycloalkyl groups, or R^5 and R^6 on the same carbon together form a C_{3-5} cycloalkyl group or oxo;
    - each of R^5 and R^6 is optionally independently substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, halogens, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and
    - each R^a is independently chosen from hydrogen and C_1-C_2 alkyl groups; and
  - R^7 is chosen from hydrogen, halogens, a cyano group, and C_3-C_{10} cycloalkyl groups optionally substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, and halogens;
- q is 1, 2, 3, or 4;
- Z is a divalent linker of formula $(L)_r$, wherein:
  - r is 1, 2, 3, 4, 5, or 6;

- each L is independently chosen from $C(R^8)(R^9)$ groups, –O–, and $–NR^b–$ groups , wherein a heteroatom in Z is not bonded to another heteroatom in Z, wherein:
  - each R^8 and R^9 is independently chosen from hydrogen, halogens, C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and
  - each R^b is independently chosen from hydrogen and C_1-C_2 alkyl groups.

3. The compound of claim 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein the compound of Formula I is a compound of Formula III-A or III-B:



(III-A) or



(III-B),

a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing,

wherein:

- the carbon denoted by * has S-stereochemistry or R-stereochemistry;
- Ring A is a phenyl, a 5-membered heteroaryl ring, or a 6-membered heteroaryl ring;- Ring D is a phenyl ring, a 5-membered heterocyclyl ring, a 6- membered

heterocyclyl ring, a 5-membered heteroaryl ring, or a 6-membered heteroaryl ring;

- each R^1 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;
- m is 0, 1, 2, 3, or 4;
- each R^2 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;
- n is 0, 1, or 2;
- each R^3 is methyl;
- each R^4 is independently chosen from halogens, an oxo group, a hydroxyl group, a cyano group, and -$(Y)_k$-R^7 groups or optionally two R^4, together with the atom(s) they are attached to, form a 5-6 membered cycloalkyl or heterocyclyl ring that is optionally and independently substituted with one or more groups chosen from halogens, C_1-C_2 alkyl groups, haloalkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups, wherein:
  - k is 0, 1, 2, 3, 4, 5, or 6;
  - each Y is independently chosen from $C(R^5)(R^6)$ groups, –O–, and $–NR^a–$ groups, wherein a heteroatom in -$(Y)_k$-R^7 is not bonded to another heteroatom in -$(Y)_k$-R^7, wherein:
    - each R^5 and R^6 is independently chosen from hydrogen, halogens, a hydroxyl group, C_1-C_4 alkyl groups, and C_{3-5} cycloalkyl groups, or R^5 and R^6 on the same carbon together form a C_{3-5} cycloalkyl group or oxo;
    - each of R^5 and R^6 is optionally independently substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, halogens, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and
    - each R^a is independently chosen from hydrogen and C_1-C_2 alkyl groups; and

- R^7 is chosen from hydrogen, halogens, a cyano group, and C_3-C_{10} cycloalkyl groups optionally substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, and halogens;

- q is 1 or 2;

- Z is a divalent linker of formula $(L)_r$, wherein:


  - r is 3, 4, or 5;

  - each L is independently chosen from $C(R^8)(R^9)$ groups, –O–, and $–NR^b–$ groups, wherein a heteroatom in Z is not bonded to another heteroatom in Z, wherein:

    - each R^8 and R^9 is independently chosen from hydrogen, halogens, C_1-C_2 alkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and

    - each R^b is independently chosen from hydrogen and C_1-C_2 alkyl groups.

4. The compound of claim 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein the compound of Formula I is a compound of Formula IV-A:



(IV-A)

a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing,

wherein:


- the carbon denoted by * has S-stereochemistry or R-stereochemistry;

- Ring D is a phenyl ring, a 5-membered heterocyclyl ring, a 6- membered heterocyclyl ring, a 5-membered heteroaryl ring, or a 6-membered heteroaryl ring;

- each R^1 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;
- m is 0, 1, 2, 3, or 4;
- each R^2 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;
- n is 0, 1, or 2;
- each R^3 is methyl;
- each R^4 is independently chosen from halogens, an oxo group, a hydroxyl group, a cyano group, and -$(Y)_k$-R^7 groups, or optionally two R^4, together with the atom(s) they are attached to, form a 5-6 membered cycloalkyl or heterocyclyl ring that is optionally and independently substituted with one or more groups chosen from halogens, C_1-C_2 alkyl groups, haloalkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups, wherein:
  - k is 0, 1, 2, 3, 4, 5, or 6;
  - each Y is independently chosen from $C(R^5)(R^6)$ groups, –O–, and –NR^a– groups, wherein a heteroatom in -$(Y)_k$-R^7 is not bonded to another heteroatom in -$(Y)_k$-R^7, wherein:
    - each R^5 and R^6 is independently chosen from hydrogen, halogens, a hydroxyl group, C_1-C_4 alkyl groups, and C_{3-5} cycloalkyl groups, or R^5 and R^6 on the same carbon together form a C_{3-5} cycloalkyl group or oxo;
    - each of R^5 and R^6 is optionally independently substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, halogens, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and
    - each R^a is independently chosen from hydrogen and C_1-C_2 alkyl groups; and
  - R^7 is chosen from hydrogen, halogens, a cyano group, and C_3-C_{10} cycloalkyl groups optionally substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, and halogens;
- q is 1 or 2;

- Z is a divalent linker of formula $(L)_r$, wherein:
  - r is 3, 4, or 5;
  - each L is independently chosen from $C(R^8)(R^9)$ groups, –O–, and $–NR^b–$ groups, wherein a heteroatom in Z is not bonded to another heteroatom in Z, wherein:
    - each R^8 and R^9 is independently chosen from hydrogen, halogens, C_1-C_2 alkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and
    - each R^b is independently chosen from hydrogen and C_1-C_2 alkyl groups.

5. The compound of claim 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein the compound of Formula I is a compound of Formula IV-B:



(IV-B),

a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing,


wherein:

- the carbon denoted by * has S-stereochemistry or R-stereochemistry;
- Ring D is a phenyl ring, a 5-membered heterocyclyl ring, a 6- membered heterocyclyl ring, a 5-membered heteroaryl ring, or a 6-membered heteroaryl ring;
- each R^1 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;
- m is 0, 1, 2, 3, or 4;

- each R^2 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;
- n is 0, 1, or 2;
- each R^3 is methyl;
- each R^4 is independently chosen from halogens, an oxo group, a hydroxyl group, a cyano group, and -$(Y)_k$-R^7 groups, or optionally two R^4, together with the atom(s) they are attached to, form a 5-6 membered cycloalkyl or heterocyclyl ring that is optionally and independently substituted with one or more groups chosen from halogens, C_1-C_2 alkyl groups, haloalkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups, wherein:
  - k is 0, 1, 2, 3, 4, 5, or 6;
  - each Y is independently chosen from $C(R^5)(R^6)$ groups, –O–, and –NR^a– groups, wherein a heteroatom in -$(Y)_k$-R^7 is not bonded to another heteroatom in -$(Y)_k$-R^7 , wherein:
    - each R^5 and R^6 is independently chosen from hydrogen, halogens, a hydroxyl group, C_1-C_4 alkyl groups, and C_{3-5} cycloalkyl groups, or R^5 and R^6 on the same carbon together form a C_{3-5} cycloalkyl group or oxo;
    - each of R^5 and R^6 is optionally independently substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, halogens, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and
    - each R^a is independently chosen from hydrogen and C_1-C_2 alkyl groups; and
  - R^7 is chosen from hydrogen, halogens, a cyano group, and C_3-C_{10} cycloalkyl groups optionally substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, and halogens;
- q is 1 or 2;
- r is 3 or 4;
- each R^8 and R^9 is independently chosen from hydrogen, halogens, C_1-C_2 alkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and

- each R^b is independently chosen from hydrogen and C_1-C_2 alkyl groups.

6. The compound of claim 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein the compound of Formula I is a compound of Formula IV-C:



(IV-C),

a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing,


wherein:

- the carbon denoted by * has S-stereochemistry or R-stereochemistry;
- each R^1 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;
- m is 0, 1, 2, 3, or 4;
- each R^2 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;
- n is 0, 1, or 2;
- each R^3 is methyl;
- each R^4 is independently chosen from halogens, an oxo group, a hydroxyl group, a cyano group, and $-(Y)_k-R^7$ groups, or optionally two R^4, together with the atom(s) they are attached to, form a 5-6 membered cycloalkyl or heterocyclyl ring that is optionally and independently substituted with one or more groups chosen from halogens, C_1-C_2 alkyl groups, haloalkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups, wherein:

- k is 0, 1, 2, 3, 4, 5, or 6;
- each Y is independently chosen from $C(R^5)(R^6)$ groups, –O–, and $–NR^a–$ groups, wherein a heteroatom in $-(Y)_k-R^7$ is not bonded to another heteroatom in $-(Y)_k-R^7$, wherein:
  - each R^5 and R^6 is independently chosen from hydrogen, halogens, a hydroxyl group, C_1-C_4 alkyl groups, and C_{3-5} cycloalkyl groups, or R^5 and R^6 on the same carbon together form a C_{3-5} cycloalkyl group or oxo;
  - each of R^5 and R^6 is optionally independently substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, halogens, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and
  - each R^a is independently chosen from hydrogen and C_1-C_2 alkyl groups; and
- R^7 is chosen from hydrogen, halogens, a cyano group, and C_3-C_{10} cycloalkyl groups optionally substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, and halogens;

- q is 1 or 2;
- r is 3 or 4;
- each R^8 and R^9 is independently chosen from hydrogen, halogens, C_1-C_2 alkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and
- each R^b is independently chosen from hydrogen and C_1-C_2 alkyl groups.

7. The compound of claim 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein the compound of Formula I is a compound of Formula V-A:



(V-A)

a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing,


wherein:

- the carbon denoted by * has S-stereochemistry or R-stereochemistry;
- Ring D is a phenyl ring, a 5-membered heterocyclyl ring, a 6- membered heterocyclyl ring, a 5-membered heteroaryl ring, or a 6-membered heteroaryl ring;
- each R^1 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;
- m is 0, 1, 2, 3, or 4;
- each R^2 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;
- n is 0, 1, or 2;
- each R^3 is methyl;
- each R^4 is independently chosen from halogens, an oxo group, a hydroxyl group, a cyano group, and -$(Y)_k$-R^7 groups, or optionally two R^4, together with the atom(s) they are attached to, form a 5-6 membered cycloalkyl or heterocyclyl ring that is optionally and independently substituted with one or more groups chosen from halogens, C_1-C_2 alkyl groups, haloalkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups, wherein:
  - k is 0, 1, 2, 3, 4, 5, or 6;

- each Y is independently chosen from $C(R^5)(R^6)$ groups, –O–, and $–NR^a–$ groups, wherein a heteroatom in $-(Y)_k-R^7$ is not bonded to another heteroatom in $-(Y)_k-R^7$, wherein:
  - each R^5 and R^6 is independently chosen from hydrogen, halogens, a hydroxyl group, C_1-C_4 alkyl groups, and C_{3-5} cycloalkyl groups, or R^5 and R^6 on the same carbon together form a C_{3-5} cycloalkyl group or oxo;
  - each of R^5 and R^6 is optionally independently substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, halogens, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and
  - each R^a is independently chosen from hydrogen and C_1-C_2 alkyl groups; and
- R^7 is chosen from hydrogen, halogens, a cyano group, and C_3-C_{10} cycloalkyl groups optionally substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, and halogens;

- q is 1 or 2;
- Z is a divalent linker of formula $(L)_r$, wherein:
  - r is 3, 4, or 5;
  - each L is independently chosen from $C(R^8)(R^9)$ groups, –O–, and $–NR^b–$ groups, wherein a heteroatom in Z is not bonded to another heteroatom in Z, wherein:
    - each R^8 and R^9 is independently chosen from hydrogen, halogens, C_1-C_2 alkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and
    - each R^b is independently chosen from hydrogen and C_1-C_2 alkyl groups.

8. The compound of claim 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein the compound of Formula I is a compound of Formula V-B:



(V-B),


a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing,

wherein:


- the carbon denoted by * has S-stereochemistry or R-stereochemistry;
- Ring D is a phenyl ring, a 5-membered heterocyclyl ring, a 6- membered heterocyclyl ring, a 5-membered heteroaryl ring, or a 6-membered heteroaryl ring;
- each R^1 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;
- m is 0, 1, 2, 3, or 4;
- each R^2 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;
- n is 0, 1, or 2;
- each R^3 is methyl;
- each R^4 is independently chosen from halogens, an oxo group, a hydroxyl group, a cyano group, and -$(Y)_k$-R^7 groups, or optionally two R^4, together with the atom(s) they are attached to, form a 5-6 membered cycloalkyl or heterocyclyl ring that is optionally and independently substituted with one or more groups chosen from halogens, C_1-C_2 alkyl groups, haloalkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups, wherein:
  - k is 0, 1, 2, 3, 4, 5, or 6;

- each Y is independently chosen from $C(R^5)(R^6)$ groups, –O–, and $–NR^a–$ groups, wherein a heteroatom in $-(Y)_k-R^7$ is not bonded to another heteroatom in $-(Y)_k-R^7$, wherein:
  - each R^5 and R^6 is independently chosen from hydrogen, halogens, a hydroxyl group, C_1-C_4 alkyl groups, and C_{3-5} cycloalkyl groups, or R^5 and R^6 on the same carbon together form a C_{3-5} cycloalkyl group or oxo;
  - each of R^5 and R^6 is optionally independently substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, halogens, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and
  - each R^a is independently chosen from hydrogen and C_1-C_2 alkyl groups; and
- R^7 is chosen from hydrogen, halogens, a cyano group, and C_3-C_{10} cycloalkyl groups optionally substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, and halogens;
- q is 1 or 2;
- r is 3, 4, or 5; and
- each R^8 and R^9 is independently chosen from hydrogen, halogens, C_1-C_2 alkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups.

9. The compound of claim 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein the compound of Formula I is a compound of Formula VI-A or VI-B:



(VI-A) or



(VI-B),

a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing,


wherein:

- the carbon denoted by * has S-stereochemistry or R-stereochemistry;
- Ring D is a phenyl ring, a 5-membered heterocyclyl ring, a 6- membered heterocyclyl ring, a 5-membered heteroaryl ring, or a 6-membered heteroaryl ring;
- each R^1 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;
- m is 0, 1, 2, 3, or 4;
- each R^2 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;
- n is 0, 1, or 2;
- each R^3 is methyl;
- each R^4 is independently chosen from halogens, an oxo group, a hydroxyl group, a cyano group, and -$(Y)_k$-R^7 groups, or optionally two R^4, together with the atom(s) they are attached to, form a 5-6 membered cycloalkyl or heterocyclyl ring that is optionally and independently substituted with one or more groups chosen from halogens, C_1-C_2 alkyl groups, haloalkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups, wherein:
  - k is 0, 1, 2, 3, 4, 5, or 6;


- each Y is independently chosen from $C(R^5)(R^6)$ groups, –O–, and $–NR^a–$ groups, wherein a heteroatom in $-(Y)_k-R^7$ is not bonded to another heteroatom in $-(Y)_k-R^7$, wherein:
  - each R^5 and R^6 is independently chosen from hydrogen, halogens, a hydroxyl group, C_1-C_4 alkyl groups, and C_{3-5} cycloalkyl groups, or R^5 and R^6 on the same carbon together form a C_{3-5} cycloalkyl group or oxo;
  - each of R^5 and R^6 is optionally independently substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, halogens, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and
  - each R^a is independently chosen from hydrogen and C_1-C_2 alkyl groups; and
- R^7 is chosen from hydrogen, halogens, a cyano group, and C_3-C_{10} cycloalkyl groups optionally substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, and halogens;

- q is 1 or 2;
- Z is a divalent linker of formula $(L)_r$, wherein:
  - r is 3, 4, or 5;
  - each L is independently chosen from $C(R^8)(R^9)$ groups, –O–, and $–NR^b–$ groups, wherein a heteroatom in Z is not bonded to another heteroatom in Z, wherein:
    - each R^8 and R^9 is independently chosen from hydrogen, halogens, C_1-C_2 alkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and
    - each R^b is independently chosen from hydrogen and C_1-C_2 alkyl groups.

10. The compound of claim 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein the compound of Formula I is a compound of Formula VI-C or VI-D:



(VI-C) or



(VI-D),

a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing,

wherein:

- the carbon denoted by * has S-stereochemistry or R-stereochemistry;
- Ring D is a phenyl ring, a 5-membered heterocyclyl ring, a 6- membered heterocyclyl ring, a 5-membered heteroaryl ring, or a 6-membered heteroaryl ring;- each R^1 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;
- m is 0, 1, 2, 3, or 4;
- each R^2 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;
- n is 0, 1, or 2;
- each R^3 is methyl;
- each R^4 is independently chosen from halogens, an oxo group, a hydroxyl group, a cyano group, and -$(Y)_k$-R^7 groups, or optionally two R^4, together with the

atom(s) they are attached to, form a 5-6 membered cycloalkyl or heterocyclyl ring that is optionally and independently substituted with one or more groups chosen from halogens, C_1-C_2 alkyl groups, haloalkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups, wherein:

- k is 0, 1, 2, 3, 4, 5, or 6;
- each Y is independently chosen from $C(R^5)(R^6)$ groups, –O–, and $–NR^a–$ groups, wherein a heteroatom in $-(Y)_k-R^7$ is not bonded to another heteroatom in $-(Y)_k-R^7$, wherein:
  - each R^5 and R^6 is independently chosen from hydrogen, halogens, a hydroxyl group, C_1-C_4 alkyl groups, and C_{3-5} cycloalkyl groups, or R^5 and R^6 on the same carbon together form a C_{3-5} cycloalkyl group or oxo;
  - each of R^5 and R^6 is optionally independently substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, halogens, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and
  - each R^a is independently chosen from hydrogen and C_1-C_2 alkyl groups; and
- R^7 is chosen from hydrogen, halogens, a cyano group, and C_3-C_{10} cycloalkyl groups optionally substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, and halogens;
- q is 1 or 2;
- r is 3 or 4; and
- each R^8 and R^9 is independently chosen from hydrogen, halogens, C_1-C_2 alkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups.

11. The compound of claim 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein Ring A is a phenyl ring, a pyridyl ring, or a pyrazolyl ring, wherein Ring A is optionally substituted with $(R^1)_m$.

12. The compound of claim 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein each R^1 is independently chosen from deuterium, C_1-C_2 alkyl groups, and a hydroxyl group, and m is 0 or 1.

13. The compound of claim 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein n is 0.


14. The compound of claim 1 or claim 5, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein Ring D is a 5-membered heteroaryl ring substituted with $(R^4)_q$.

15. The compound of claim 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein Ring D is a phenyl ring, pyridinyl ring, pyrazolyl ring, imidazolidinone ring, a pyrrolidinone ring, or a pyridinone ring, wherein Ring D is substituted with $(R^4)_q$.


16. The compound of claim 1 or claim 5, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein Ring D is a pyrazolyl ring, or a pyridinone ring, wherein Ring D is substituted with $(R^4)_q$.

17. The compound of claim 3, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein Ring D is a pyrazolyl ring, wherein Ring D is substituted with $(R^4)_q$.

18. The compound of claim 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein Ring D is




,



, or ,

wherein  indicates the point of attachment of Ring D to Ring B .

19. The compound of claim 1 or claim 5, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein Ring D is



,

wherein  indicates the point of attachment of Ring D to Ring B .

20. The compound of claim 19, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein each R^4 is independently chosen from an oxo group or $–(Y)_k\text{-}R^7$ groups, wherein:

- k is 0, 1, 2, 3, 4, 5, or 6;
- each Y is independently chosen from $C(R^5)(R^6)$ groups, –O–, and $–NR^a–$ groups, wherein a heteroatom in $\text{-}(Y)_k\text{-}R^7$ is not bonded to another heteroatom in $\text{-}(Y)_k\text{-}R^7$, and wherein:
  - each R^5 and R^6 is independently chosen from hydrogen, deuterium, halogens, a hydroxyl group, C_1-C_4 alkyl groups, and $C_{3\text{-}5}$ cycloalkyl groups, or R^5 and R^6 on the same carbon together form a $C_{3\text{-}5}$ cycloalkyl group;


- each of R^5 and R^6 is optionally independently substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, halogens, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and
- each R^a is independently chosen from hydrogen and C_1-C_2 alkyl groups; and















- R^7 is chosen from hydrogen, halogens, a cyano group, and C_3-C_{10} cycloalkyl groups optionally substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, and halogens.















21. The compound of claim 19, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein each R^4 is independently chosen from an oxo group or -O-$(Y)_k$-R^7 groups, wherein:









- k is 0, 1, 2, 3, 4, or 5;
- each Y is independently chosen from $C(R^5)(R^6)$ groups, –O–, and –NR^a– groups, wherein a heteroatom in -$(Y)_k$-R^7 is not bonded to another heteroatom in -$(Y)_k$-R^7, and wherein:
  - each R^5 and R^6 is independently chosen from hydrogen, deuterium, halogens, a hydroxyl group, C_1-C_4 alkyl groups, and $C_{3\text{-}5}$ cycloalkyl groups, or R^5 and R^6 on the same carbon together form a $C_{3\text{-}5}$ cycloalkyl group or oxo;
  - each of R^5 and R^6 is optionally independently substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, halogens, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and
  - each R^a is independently chosen from hydrogen and C_1-C_2 alkyl groups; and
- R^7 is chosen from hydrogen, halogens, a cyano group, and C_3-C_{10} cycloalkyl groups optionally substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, and halogens.

22. The compound of claim 19, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein each R^4 is independently chosen from




F3C
O
,

OH
F3C
O
,

,

,

,

O
,

O
,

O
,

,

,

,

O
,

O
,

O
,


O
O
,

OH
O
,

,

,

,

F
F
,

F3C
,

O
,

O
,

O
,

O
,

O
,

O
,

O
,









, and

wherein  indicates the point of attachment of R^4 to Ring D.

23. The compound of claim 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein k is 3, 4, 5, or 6.

24. The compound of claim 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein q is 1.

25. The compound of claim 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein Z is a divalent linker of formula $(L)_r$, wherein:

- r is 3, 4, or 5;

- each L is independently chosen from $C(R^8)(R^9)$ groups, –O–, and $–NR^b–$ groups, wherein a heteroatom in Z is not bonded to another heteroatom in Z, and wherein:
  - each R^8 and R^9 is independently chosen from hydrogen and deuterium; and
  - each R^b is independently chosen from hydrogen and C_1-C_2 alkyl groups.

26. The compound of claim 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein Z is a divalent linker of formula $(L)_r$, wherein:
- r is 3, 4, or 5;
- each L is independently chosen from $C(R^8)(R^9)$ groups and $–NR^b–$ groups, wherein a heteroatom in Z is not bonded to another heteroatom in Z, and:
  - each R^8 and R^9 is independently chosen from hydrogen and deuterium; and
  - each R^b is independently chosen from hydrogen and methyl.

27. The compound of claim 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein Z is a divalent linker of formula $(L)_r$, wherein:
- r is 3, 4, or 5;
- each L is independently chosen from $C(R^8)(R^9)$ groups and $–NR^b–$ groups, wherein a heteroatom in Z is not bonded to another heteroatom in Z, and wherein:
  - each R^8 and R^9 is independently chosen from hydrogen and deuterium; and
  - each R^b is hydrogen.

28. The compound of claim 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein Z is a divalent linker of formula $(L)_r$, wherein:
- r is 3, 4, or 5;
- each L is independently chosen from $C(R^8)(R^9)$ groups, –O–, and $–NR^b–$ groups, wherein a heteroatom in Z is not bonded to another heteroatom in Z, wherein:
  - each R^8 and R^9 is hydrogen; and
  - each R^b is independently chosen from hydrogen and C_1-C_2 alkyl groups.

29. The compound of claim 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein each R^3 is independently CD_3.

30. The compound of claim 5, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein:

- r is 3 or 4;
- each R^8 and R^9 is independently chosen from hydrogen and deuterium; and
- each R^b is independently chosen from hydrogen and C_1-C_2 alkyl groups.

31. The compound of claim 5, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein:

- r is 3 or 4;
- each R^8 and R^9 is independently chosen from hydrogen and deuterium; and
- each R^b is hydrogen.


32. The compound of claim 6, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein:

- r is 3 or 4; and
- each R^8 and R^9 is independently chosen from hydrogen and deuterium.


33. The compound of claim 6, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein:

- r is 3 or 4; and
- each R^8 and R^9 is hydrogen.











34. A compound selected from:



























Compound 1

























Compound 2













 **enantiomer 2** , Compound 3	 , Compound 4
 , Compound 5	 , Compound 6
 , Compound 7	 , Compound 8
 , Compound 9	 , Compound 10
 , Compound 11	 , Compound 12













 , Compound 13	 , Compound 14
 , Compound 15	 , Compound 16
 , Compound 17	 , Compound 18
 , Compound 19	 , Compound 20
 , Compound 21	 , Compound 22
 , Compound 23	 , Compound 24













 , Compound 25	 , Compound 26
 , Compound 27	 , Compound 28
 , Compound 29	 , Compound 30
 , Compound 31	 , Compound 32
 , Compound 33	 , Compound 34
 , Compound 35	 , Compound 36













 , Compound 37	 , Compound 38
 , Compound 39	 , Compound 40
 , Compound 41	 , Compound 42
 , Compound 43	 enantiomer 1 , Compound 44
 , Compound 45	 , Compound 46













 , Compound 47	 , Compound 48
 , Compound 49	 , Compound 50
 , Compound 51	 , Compound 52
 , Compound 53	 , Compound 54
 , Compound 55	 , Compound 56
 , Compound 57	 , Compound 58













 , Compound 59	 , Compound 60
 , Compound 61	 , Compound 62
 , Compound 63	 , Compound 64
 , Compound 65	 , Compound 66
 , Compound 67	 , Compound 68
 , Compound 69	 , Compound 70











 , Compound 71	 , Compound 72
 , Compound 73	 , Compound 74
 , Compound 75	 , Compound 76
 , Compound 77	 , Compound 78
 , Compound 79	 , Compound 80
 , Compound 81	 , Compound 82













 , Compound 83	 , Compound 84
 , Compound 85	 , Compound 86
 , Compound 87	 , Compound 88
 , Compound 89	 , Compound 90
 , Compound 91	 , Compound 92
 , Compound 93	 , Compound 94











 , Compound 95	 , Compound 96
 , Compound 97	 , Compound 98
 , Compound 99	 , Compound 100
 , Compound 101	 , Compound 102
 , Compound 103	 , Compound 104
 , Compound 105	 , Compound 106











 , Compound 107	 , Compound 108
 , Compound 109	 , Compound 110
 , Compound 111	 , Compound 112
 , Compound 113	 , Compound 114
 , Compound 115	 , Compound 116
 , Compound 117	 , Compound 118













 Compound 119	 Compound 120
 Compound 121	 Compound 122
 Compound 123	 Compound 124
 Compound 125	 Compound 126
 Compound 127	 Compound 128
 Compound 129	 Compound 130











 , Compound 131	 , Compound 132
 , Compound 133	 , Compound 134
 , Compound 135	 , Compound 136
 , Compound 137	 , Compound 138
 , Compound 139	 , Compound 140











 , Compound 141	 , Compound 142
 , Compound 143	 , Compound 144
 , Compound 145	 , Compound 146
 , Compound 147	 , Compound 148
 , Compound 149	 , Compound 150
 , Compound 151	 , Compound 152











 , Compound 153	 , Compound 154
 , Compound 155	 , Compound 156
 , Compound 157	 , Compound 158
 , Compound 159	 , Compound 160
 , Compound 161	 , Compound 162











 , Compound 163	 , Compound 164
 , Compound 165	 , Compound 166
 , Compound 167	 , Compound 168
 , Compound 169	 , Compound 170
 , Compound 171	 , Compound 172











 , Compound 173	 , Compound 174
 , Compound 175	 , Compound 176
 , Compound 177	 , Compound 178
 , Compound 179	 , Compound 180
 , Compound 181	 , Compound 182
 , Compound 183	 , Compound 184













 , Compound 185	 , Compound 186
 , Compound 187	 , Compound 188
 , Compound 189	 , Compound 190
 , Compound 191	 , Compound 192
 , Compound 193	 , Compound 194











 , Compound 195	 , Compound 196
 , Compound 197	 , Compound 198
 , Compound 199	 , Compound 200
 , Compound 201	 , Compound 202
 , Compound 203	 , Compound 204











 , Compound 205	 , Compound 206
 , Compound 207	 , Compound 208
 , Compound 209	 , Compound 210
 , Compound 211	 , Compound 212
 , Compound 213	 , Compound 214













 , Compound 215	 , Compound 216
 , Compound 217	 , Compound 218
 , Compound 219	 , Compound 220
 , Compound 221	 , Compound 222
 , Compound 223	 , Compound 224













 , Compound 225	 , Compound 226
 , Compound 227	 , Compound 228
 , Compound 229	 , Compound 230
 , Compound 231	 , Compound 232
 , Compound 233	 enantiomer 1 , Compound 234











 enantiomer 2 , Compound 235	 , Compound 236
 , Compound 237	 , Compound 238
 , Compound 239	 , Compound 240
 , Compound 241	 , Compound 242
 , Compound 243	 , Compound 244
 , Compound 245	 , Compound 246










 , Compound 247	 , Compound 248
 , Compound 249	 , Compound 250
 , Compound 251	 , Compound 252
 , Compound 253	 , Compound 254
 , Compound 255	 , Compound 256

 , Compound 257	 , Compound 258
 , Compound 259	 , Compound 260
 , Compound 261	 , Compound 262
 , Compound 263	 , Compound 264
 , Compound 265	 , Compound 266

 , Compound 267	 , Compound 268
 , Compound 269	 , Compound 270
 , Compound 271	 , Compound 272
 , Compound 273	 , Compound 274
 , Compound 275	 , Compound 276
 , Compound 277	 , Compound 278

 , Compound 279	 , Compound 280
 , Compound 281	 , Compound 282
 , Compound 283	 , Compound 284
 , Compound 285	 , Compound 286
 , Compound 287	 , Compound 288
 , Compound 289	 , Compound 290

 , Compound 291	 , Compound 292
 , Compound 293	 , Compound 294
 , Compound 295	 , Compound 296
 , Compound 297	 , Compound 298
 , Compound 299	 , Compound 300


 , Compound 301	 , Compound 302
 , Compound 303	 , Compound 304
 , Compound 305	 , Compound 306
 , Compound 307	 , Compound 308
 , Compound 309	

a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the compounds, or a pharmaceutically acceptable salt of any deuterated derivatives of those compounds.

35. The compound of claim 1, wherein the compound is in the form of a pharmaceutically acceptable salt.

36. A pharmaceutical composition comprising a compound of claim 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, and optionally one or more of:


(a) Compound II:




(II),

a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing;

(b) Compound III or Compound III-d:



(III),




(III-d)

a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing; and

(c) a pharmaceutically acceptable carrier.


37. A compound of the formula:



(Compound 195),

a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing.

38. A compound of the formula:



(Compound 195),

or a pharmaceutically acceptable salt thereof.

39. The compound of claim 38, wherein the compound is in the form of a pharmaceutically acceptable salt.


40. The compound of claim 39, wherein the pharmaceutically acceptable salt is a calcium salt.

41. The compound of claim 39, wherein the pharmaceutically acceptable salt is a sodium salt.

42. The compound of claim 39, wherein the pharmaceutically acceptable salt is a potassium salt.

43. A pharmaceutical composition comprising the compound, salt, or deuterated derivative of any one of claims 37 to 42, and optionally one or more of:


(a) Compound II:




(II),

a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing;

(b) Compound III or Compound III-d:



(III),




(III-d)

a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing; and

(c) a pharmaceutically acceptable carrier.

44. A pharmaceutical composition comprising the pharmaceutically acceptable salt of any one of claims 37 to 42, and optionally one or more of:


(a) Compound II:




(II),

a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing;

(b) Compound III or Compound III-d:



(III),




(III-d)

a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing; and

(c) a pharmaceutically acceptable carrier.


45. A method of preparing a compound of Formula (**I**):



(**I**),

a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, comprising

coupling the NH group of Ring C and the Q^b group of Ring B of a compound of Formula (**Y-I**):



(**Y-I**),

a salt thereof, or a deuterated derivative of any of the foregoing, wherein:


- Q^b is a halogen;
- Ring A is a phenyl, a 5-membered heteroaryl ring, or a 6-membered heteroaryl ring;
- Ring B is a pyridinyl ring;
- Ring D is a phenyl ring, a 5-membered heterocyclyl ring, a 6- membered heterocyclyl ring, a 5-membered heteroaryl ring, or a 6-membered heteroaryl ring;
- X is O, NH, or an N(C_1-C_4 alkyl);
- each R^1 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;

- m is 0, 1, 2, 3, or 4;
- each R^2 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;
- n is 0, 1, or 2;
- each R^3 is methyl;
- each R^4 is independently chosen from halogens, an oxo group, a hydroxyl group, a cyano group, and -$(Y)_k$-R^7 groups, or optionally two R^4, together with the atom(s) they are attached to, form a 5-6 membered cycloalkyl or heterocyclyl ring that is optionally and independently substituted with one or more groups chosen from halogens, C_1-C_2 alkyl groups, haloalkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; wherein:
  - k is 0, 1, 2, 3, 4, 5, or 6;
  - each Y is independently chosen from $C(R^5)(R^6)$ groups, –O–, and –NR^a– groups, wherein a heteroatom in -$(Y)_k$-R^7 is not bonded to another heteroatom in -$(Y)_k$-R^7, wherein:
    - each R^5 and R^6 is independently chosen from hydrogen, halogens, a hydroxyl group, C_1-C_4 alkyl groups, and C_{3-5} cycloalkyl groups, or R^5 and R^6 on the same carbon together form a C_{3-5} cycloalkyl group or oxo;
    - each of R^5 and R^6 is optionally independently substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, halogens, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and
    - each R^a is independently chosen from hydrogen and C_1-C_2 alkyl groups; and
- R^7 is chosen from hydrogen, halogens, a cyano group, and C_3-C_{10} cycloalkyl groups optionally substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, and halogens;
- q is 1, 2, 3 or 4; and
- Z is a divalent linker of formula $(L)_r$, wherein:
  - r is 1, 2, 3, 4, 5, or 6;


- each L is independently chosen from $C(R^8)(R^9)$ groups, –O–, and $–NR^b–$ groups, wherein a heteroatom in Z is not bonded to another heteroatom in Z, wherein:
  - each R^8 and R^9 is independently chosen from hydrogen, halogens, C_1-C_2 haloalkyl groups, C_1-C_2 alkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and
  - each R^b is independently chosen from hydrogen and C_1-C_2 alkyl groups;

to form a compound of Formula (**I**), a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing.

46. A method of preparing a compound of Formula (**I**)





(**I**),

a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein Ring D is 

, comprising

reacting a compound of Formula (**X**), a salt thereof, or a deuterated derivative of any of the foregoing, with a compound of Formula (**Z-1**), a salt thereof, or a deuterated derivative of any of the foregoing:





wherein:

- Q^a is a halogen;
- Ring A is a phenyl, a 5-membered heteroaryl ring, or a 6-membered heteroaryl ring;
- Ring B is a pyridinyl ring;
- Ring D is a phenyl ring, a 5-membered heterocyclyl ring, a 6- membered heterocyclyl ring, a 5-membered heteroaryl ring, or a 6-membered heteroaryl ring;
- X is O, NH, or an N(C1-C4 alkyl);
- each R^1 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;
- m is 0, 1, 2, 3, or 4;
- each R^2 is independently chosen from C_1-C_2 alkyl groups, C_1-C_2 alkoxyl groups, C_1-C_2 haloalkyl groups, C_1-C_2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;

- n is 0, 1, or 2;
- each R^3 is methyl;
- each R^4 is independently chosen from halogens, an oxo group, a hydroxyl group, a cyano group, and $-(Y)_k-R^7$ groups, or optionally two R^4, together with the atom(s) they are attached to, form a 5-6 membered cycloalkyl or heterocyclyl ring that is optionally and independently substituted with one or more groups chosen from halogens, C_1-C_2 alkyl groups, haloalkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; wherein:
  - k is 0, 1, 2, 3, 4, 5, or 6;
  - each Y is independently chosen from $C(R^5)(R^6)$ groups, –O–, and $–NR^a–$ groups, wherein a heteroatom in $-(Y)_k-R^7$ is not bonded to another heteroatom in $-(Y)_k-R^7$, wherein:
    - each R^5 and R^6 is independently chosen from hydrogen, halogens, a hydroxyl group, C_1-C_4 alkyl groups, and C_{3-5} cycloalkyl groups, or R^5 and R^6 on the same carbon together form a C_{3-5} cycloalkyl group or oxo;
    - each of R^5 and R^6 is optionally independently substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, halogens, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and
    - each R^a is independently chosen from hydrogen and C_1-C_2 alkyl groups; and
  - R^7 is chosen from hydrogen, halogens, a cyano group, and C_3-C_{10} cycloalkyl groups optionally substituted with one or more groups chosen from C_1-C_2 alkyl groups, C_1-C_2 haloalkyl groups, and halogens;
- q is 1, 2, 3 or 4; and
- Z is a divalent linker of formula $(L)_r$, wherein:
  - r is 1, 2, 3, 4, 5, or 6;
  - each L is independently chosen from $C(R^8)(R^9)$ groups, –O–, and $–NR^b–$ groups, wherein a heteroatom in Z is not bonded to another heteroatom in Z, wherein:

- each R^8 and R^9 is independently chosen from hydrogen, halogens, C_1-C_2 haloalkyl groups, C_1-C_2 alkyl groups, a hydroxyl group, C_1-C_2 alkoxyl groups, and C_1-C_2 haloalkoxyl groups; and
- each R^b is independently chosen from hydrogen and C_1-C_2 alkyl groups.